Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in BRAF-Altered Tumors (AcSé)
NCT02304809Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Oct 2014
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in solid tumor, hematologic cancers and cancer, sponsored by Unicancer. Primary endpoint: Objective Response Rate at 8 weeks. Started Oct 2014; status: active, not recruiting.
02
Drugs
vemurafenib
03
Conditions
solid tumorhematologic cancerscancer
Beyond the preview
Go deeper on NCT02304809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304809.